Referencias►
1.
Kane S, Goldberg MJ. Use of bromelain for mild ulcerative colitis [letter].
Ann Intern Med.
2000;132:680.
2.
Taussig SJ, Yokoyama MM, Chinen A, et al. Bromelain, a proteolytic enzyme and its clinical application. A review.
Hiroshima J Med Sci. 1975;24:185 - 193.
3.
Taussig SJ, Batkin S. Bromelain, the enzyme complex of pineapple (
Ananas comosus) and its clinical application. An update.
J Ethnopharmacol. 1988;22:191 - 203.
4.
Moshal MG. Nutrizym as a pancreatic enzyme replacement.
S Afr Med J.
1974;48:1489 - 1490.
5.
Knill-Jones RP, Pearce H, Batten J, et al. Comparative trial of Nutrizym in chronic pancreatic insufficiency.
Br Med J.
1970;4:21 - 24.
6.
Goodchild MC, Sagaro E, Brown GA, et al. Comparative trial of pancrex V forte and nutrizym in treatment of malabsorption in cystic fibrosis.
Br Med J.
1974;3:712 - 714.
7.
Moss JN, Frazier CV, Martin GJ. Bromelains. The pharmacology of the enzymes.
Arch Int Pharmacodyn Ther.
1963;145:166 - 188.
8.
Tinozzi S, Venegoni A. Effect of bromelain on serum and tissue levels of amoxycillin.
DrugsExp Clin Res.
1978;4:39 - 44.
9.
Luerti M, Vignali M. Influence of bromelain on penetration of antibiotics in uterus, salpinx and ovary.
Drugs Exp Clin Res.
1978;4:45 - 48.
10.
Mori S, Ojima Y, Hirose T, et al. The clinical effect of proteolytic enzyme containing bromelain and trypsin on urinary tract infection evaluated by double blind method.
Acta Obstet Gynaecol Jpn.
1972;19:147 - 153.
11.
Smyth RD, Brennan R, Martin GJ. Studies establishing the absorption of bromelains (proteolytic enzymes) from the gastrointestinal tract.
Exp Med Surg.
1964;22: 46 - 59.
12.
Miller JM, Ginseberg M, McElfatrick GC, et al. The administration of bromelain orally in the treatment of inflammation and edema.
Exp Med Surg.
1964;22:293 - 299.
13.
Castell JV, Friedrich G, Kuhn CS, et al. Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake.
Am J Physiol.
1997;273:G139 - G146.
14.
Izaka KI, Yamada M, Kawano T. Gastrointestinal absorption and antiinflammatory effect of bromelain.
Jpn J Pharmacol. 1972;22:519 - 534.
15.
Seligman B. Bromelain: an anti-inflammatory agent.
Angiology. 1962;13:508 - 510.
16.
Seligman B. Oral bromelains as adjuncts in the treatment of acute thrombophlebitis.
Angiology.
1969;20:22 - 26.
17.
Pirotta F, De Giuli-Morghen C. Bromelain - a deeper pharmacological study. Note I. Antiinflammatory and serum fibrinolytic activity after oral administration in the rat.
Drugs Exp Clin Res. 1978;4:1 - 20.
18.
Smyth RD, Brennan R, Martin GJ. Systemic biochemical changes following the oral administration of a proteolytic enzyme, bromelain.
Arch Int Pharmacodyn Ther.
1962;136:230 - 236.
19.
Livio M. Effect of bromelain on fibrinogen level, prothrombin complex factors and platelet aggregation in the rat.
Drugs Exp Clin Res.
1978;4:49 - 53.
20.
Opher AW, Miller JM. The enzymatic properties of bromelain.
Exp Med Surg.
1964;22:281 - 292.
21.
Didisheim P, Lewis JH. Fibrinolytic and coagulant activities of certain snake venoms and proteases.
Proc Soc Exp Biol Med.
1956;93:10 - 13.
22.
Vellini M, Desideri D, Milanese A, et al. Possible involvement of eicosanoids in the pharmacological action of bromelain.
Arzneimittelforschung.
1986;36:110 - 112.
23.
Metzig C, Grabowska E, Eckert K, et al. Bromelain proteases reduce human platelet aggregation in vitro, adhesion to bovine endothelial cells and thrombus formation in rat vessels in vivo.
In Vivo.
1999;13:7 - 12.
24.
Heinicke RM, Wal L van der, Yokoyama M. Effect of bromelain (Ananase) on human platelet aggregation.
Experientia.
1972;28: 844 - 845.
25.
Taussig SJ, Batkin S. Bromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application. An update.
J Ethnopharmacol.
1988;22:191 - 203.
26.
Felton GE. Fibrinolytic and antithrombotic action of bromelain may eliminate thrombosis in heart patients.
Med Hypotheses.
1980;6:1123 - 1133.
27.
Bodi T. Modifications of tissue permeability by orally administered proteolytic enzymes in man.
Exp Med Surg.
1965;(suppl):51 - 62.
28.
Lotz-Winter H. On the pharmacology of bromelain: an update with special regard to animal studies on dose-dependent effects.
Planta Med.
1990;56:249 - 253.
29.
Kumakura S, Yamashita M, Tsurufuji S. Effect of bromelain on kaolin-induced inflammation in rats.
Eur J Pharmacol.
1988;150:295 - 301.
30.
Barrett AJ, Starkey PM. The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism.
Biochem J.
1973;133:709 - 724.
31.
Zatuchni GI, Colombi DJ. Bromelains therapy for the prevention of episiotomy pain.
Obstet Gynecol.
1967;29:275 - 278.
32.
Howat RC, Lewis GD. The effect of bromelain therapy on episiotomy wounds - a double-blind controlled clinical trial.
J Obstet Gynaecol Br Commonw.
1972;79:951 - 953.
33.
Spaeth GL. The effect of bromelains on the inflammatory response caused by cataract extraction: a double-blind study.
Eye Ear Nose Throat Mon.
1968;47:634 - 639.
34.
Tassman GC, Zafran JN, Zayon GM. Evaluation of a plant proteolytic enzyme for the control of imflammation and pain.
J Dent Med.
1964;19:73 - 77.
35.
Gylling U, Rintala A, Taipale S, et al. The effect of a proteolytic enzyme combinate (bromelain) on the postoperative oedema by oral application. A clinical and experimental study.
Acta Chir Scand.
1966;131:193 - 196.
36.
Blonstein JL. Control of swelling in boxing injuries.
Practitioner. 1969;203:206.
37.
Masson M. Bromelain in blunt injuries of the locomotor system. A study of observed applications in general practice [in German; English abstract].
Fortschr Med. 1995;113:303 - 306.
38.
Ryan RE. A double-blind clinical evaluation of bromelains in the treatment of acute sinusitis.
Headache.
1967;7:13 - 17.
39.
Taub SJ. The use of ananase in sinusitis: A study of 60 patients.
Eye Ear Nose Throat Mon.
1966;45:96, 98.
40.
Seltzer AP. Adjunctive use of bromelains in sinusitis: a controlled study.
Eye Ear Nose Throat Mon.
1967;46:1281 - 1288.
41.
Blumenthal M, ed.
The Complete German Commission E Monographs, Therapeutic Guide to Herbal Medicines. Boston, Mass: Integrative Medicine Communications; 1998:94.
42.
Moss JN, Frazier CV, Martin GJ. Bromelains. The pharmacology of the enzymes.
Arch Int Pharmacodyn Ther.
1963;145:166 - 188.
43.
Brakebusch M, Wintergerst U, Petropoulou T, et al. Bromelain is an accelerator of phagocytosis, respiratory burst and killing of
Candida albicans
by human granulocytes and monocytes.
Eur J Med Res.
2001;6:193 - 200.
44.
Desser L, Rehberger A, Paukovits W. Proteolytic enzymes and amylase induce cytokine production in human peripheral blood mononuclear cells in vitro.
Cancer Biother.
1994;9:253 - 263.
45.
Seltzer AP. Minimizing post-operative edema and ecchymoses by the use of an oral enzyme preparation (bromelain): a controlled study of 53 rhinoplasty cases.
Eye Ear Nose Throat Mon.
1962;41:813 - 817.
46.
Frank SC. Use of chymoral as an anti-inflammatory agent following surgical trauma.
J Am Podiatr Assoc.
1965;55:706 - 709.
47.
Gutfreund A, Effect of oral bromelain on blood pressure and heart rate of hypertensive patients.
Hawaii Medical Journal
1978;37:143-146
48.
Stone MB, Merrick MA, Ingersoll CD, et al. Preliminary comparison of bromelain and ibuprofen for Delayed Onset Muscle Soreness management.
Clin J Sport Med.
2002;12:373-378.
